California has launched a program to manufacture and sell lower-cost insulin to people with diabetes. State officials say ...

Key Takeaways California’s CalRx insulin pens will launch Jan. 1 at $11 each, or $55 for a five-packThe state has invested $100 million to lower insulin costsThe effort could save patients $2,000 to ...

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

The state of California is teaming up with the nonprofit generic drug maker Civica Rx and Biocon Biologics to offer an interchangeable biosimilar insulin glargine pen for $11 beginning January 1, 2026 ...

This is read by an automated voice. Please report any issues or inconsistencies here. Gov. Gavin Newsom said $11 insulin pens will soon be available through the state’s pharmaceutical label.

California will begin selling long-acting, low-cost insulin in January, becoming the first state to bypass major pharmaceutical companies, Gov. Gavin Newsom (D-CA) announced Thursday. The move marks a ...

California will start selling low-cost insulin on Jan. 1, nearly three years after Gov. Gavin Newsom announced a plan to make lifesaving medications more affordable for folks with diabetes. The ...

Gov. Gavin Newsom speaks during a news conference announcing $11 insulin and prescription drugs with the CalRx program inside a Cedars-Sinai pharmacy in Los Angeles on Thursday. The effort is part of ...

Adocia and Tonghua Dongbao have announced positive topline results from a phase 3 clinical trial of BioChaperone Lispro (THDB0206 injection), an ultra-rapid insulin formulation, in adults with type 1 ...

This Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection) conducted in China in people with Type 1 Diabetes, successfully demonstrated, in comparison with standard of care Humalog®: Non ...

LYON, France, October 15, 2025--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and ...